Key result
Rituximab therapy induced a marked reduction in tumor volume and sustained remission at 6 months in a patient with primary cardiac B-cell non-Hodgkin's lymphoma.
Case Report (n=1)
No
Rituximab may be a safe and effective treatment option for the extremely rare and highly fatal primary cardiac B-cell lymphoma.
No takes yet. Share an insight, caveat, or question.
May support rituximab consideration in rare primary cardiac lymphoma; leaves open confirmation in prospective studies.
Nakagawa et al. (2004) conducted a case report in Primary cardiac B-cell non-Hodgkin's lymphoma (n=1). Rituximab was evaluated on Tumor regression and remission. Rituximab therapy induced a marked reduction in tumor volume and sustained remission at 6 months in a patient with primary cardiac B-cell non-Hodgkin's lymphoma.